From Lab to 2,400 Patients: How Saudi's First National CGT Hub is Transforming Therapy Access

Saudi Arabia is taking a bold step in advanced therapies with the Kingdom's first national cell and gene therapy hub at King Faisal Specialist Hospital. Once operational, the facility will deliver 2,400 treatment doses annually, meet 9% of national CGT demand, and reduce healthcare costs by an estimated 8 billion riyals (~$2B) by 2030. Other facilities like KAIMRC and Riyadh Bio Central are working on these too Built with GMP compliance, AI-driven quality control, and a modular, scalable design, the hub is not just a facility, it is a blueprint for precision medicine, advanced manufacturing, and expanded patient access. Join this session to explore how Saudi Arabia is turning strategic vision into measurable patient and economic impact, and learn what opportunities this milestone creates for partners, investors, and innovators in the region's rapidly growing CGT ecosystem. "